All In Biotech

Drug Trial Radar · NCT02153502

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 206 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

206

Actual

Start

Jul 1, 2014

Primary completion

Feb 1, 2016

Study completion Feb 1, 2016

Sponsor

Sponsor type
Industry
First posted
Jun 3, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this 10-week study are to evaluate the efficacy, safety, and tolerability of AVP 786 as an adjunctive therapy compared with placebo in patients with major depressive disorder (MDD) who have shown an inadequate response to standard antidepressant treatment. A secondary objective of this study is to assess the pharmacokinetics (PK) of AVP-786 and potential correlations with pharmacodynamic effects.

Conditions

  • Depressive Disorder, Treatment-Resistant

Interventions

  • AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)Drug

    AVP-786 capsules administered orally.

  • PlaceboDrug

    Matching placebo capsules administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Montgomery-Ǻsberg Depression Rating Scale (MADRS) total scoreTime frame: Visit 5 (Day 70) Week 10

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Bellflower, California

  • Site not named

    Costa Mesa, California

  • Site not named

    Garden Grove, California

  • Site not named

    Lomita, California

  • Site not named

    Oceanside, California

  • Site not named

    Riverside, California

  • Site not named

    Santa Ana, California

  • Site not named

    Sherman Oaks, California

  • Site not named

    Denver, Colorado

  • Site not named

    Bradenton, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orange City, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Decatur, Georgia

  • Site not named

    Hoffman Estates, Illinois

  • Site not named

    Valparaiso, Indiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Glen Burnie, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Brooklyn, New York

  • Site not named

    New York, New York

  • Site not named

    Staten Island, New York

  • Site not named

    Garfield Heights, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Tulsa, Oklahoma

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Murray, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.